On Tuesday, Shares of Weatherford International Plc (NYSE:WFT), added 0.85% and closed at $5.91 in the last trading session. WFT stock opened its last trade at $5.87 and after floating in a range of $5.87 to $6.05. The company’s Market capitalization is $5.25 Billion with the total Outstanding Shares of 896.15 million. During the 52-week trading session the minimum price at which share price traded, registered at $4.71 and reached to max level of $11.49. The Earnings per Share of the company stands at $-3.01. Weatherford International public limited company, together with its auxiliaries, operates as a multinational oilfield service company worldwide. It offers equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells. The company operates through three business groups: Formation Evaluation and Well Construction, Completion and Production, and Land Drilling Rigs. The Formation Evaluation and Well Construction business group provides managed-pressure drilling, drilling services, tubular running services, drilling tools, wireline services, testing and production services, re-entry and fishing services, cementing, liner systems, integrated laboratory services, and surface logging systems.
Shares of St. Jude Medical, Inc. (NYSE:STJ), gained 2.29% and closed at $79.44 in the last trading session. STJ stock opened its last trade at $78.87 and after floating in a range of $78.62 to $79.68. The company’s Market capitalization is $22.54 Billion with the total Outstanding Shares of 284.93 million. During the 52-week trading session the minimum price at which share price traded, registered at $48.83 and reached to max level of $84.00. The Earnings per Share of the company stands at $2.30. St. Jude Medical, Inc. (STJ), a global medical device company, today announced the launch of the ADO II AS (AMPLATZER™ Duct Occluder II Additional Sizes) pediatric clinical trial. The U.S. IDE clinical trial will evaluate the safety and effectiveness of the St. Jude Medical™ AMPLATZER™ Duct Occluder II AS (ADO II AS), a first-of-its-kind device specifically designed for closure of the small patent ductus arteriosus (PDA). St. Jude Medical now has two ongoing U.S. cardiology IDE clinical trials for pediatric patients. In 2014, the company launched the HALO trial to evaluate the safety and effectiveness of the SJM™ Masters HP Series 15mm mechanical heart valve, the smallest pediatric mechanical heart valve in the world.
Congenital heart disease (CHD) is the most common cause of major congenital anomalies, representing a major global health challenge. Every year CHD affects 1.35 million babies worldwide. Nearly 25 percent of babies with a congenital heart defect require surgery during their first year.
“The patients who would be eligible for this study are the tiniest and most fragile we care for—severely premature newborns who in many cases are critically ill from the presence of a patent ductus arteriosus (PDA),” said national investigator Dr. Evan Zahn, director of the Guerin Family Congenital Heart Program in the Cedars-Sinai Heart Institute and Department of Pediatrics at Cedars‐Sinai Medical Center in Los Angeles. “The AMPLATZER Duct Occluder II AS will provide an experimental option to surgery. Surgery has many risks in this delicate population and a minimally invasive approach is desperately needed for this fairly common and often quiet serious problem.”